Specific stimulation of migration of human keratinocytes by mu-opiate receptor agonists

Détails

ID Serval
serval:BIB_04B99A0E77CC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Specific stimulation of migration of human keratinocytes by mu-opiate receptor agonists
Périodique
Journal of Receptor and Signal Transduction Research
Auteur(s)
Bigliardi  P. L., Buchner  S., Rufli  T., Bigliardi-Qi  M.
ISSN
1079-9893 (Print)
Statut éditorial
Publié
Date de publication
11/2002
Volume
22
Numéro
1-4
Pages
191-9
Notes
In Vitro
Journal Article --- Old month value: Feb-Nov
Résumé
There are several indications that neuropeptides, especially the opiate receptor agonists, modulate the immune response by stimulating the formation of granulation tissue and enhancing the reepithelialization. We observed that the mu-opiate receptor ligand beta-endorphin stimulates the migration of cultured human foreskin keratinocytes. After 1 hour exposure to 1 microM beta-endorphin, the keratinocytes experienced an increase of cell diameter by cellular elongation and stimulation of migration. Dynorphin had a lesser effect under the same condition. The opiate receptor antagonist naltrexone significantly reduced the effect of beta-endorphin on keratinocyte migration. This migratory effect of mu-opiate receptor agonists in vitro indicates that the opioid peptides, released in wounds, could play a key role in the final reepithelialization and tissue regeneration in wound healing. This new knowledge will help us not only to understand the mechanism of wound healing but also to improve the therapeutic strategy in the healing of painful chronic wounds.
Mots-clé
Cell Movement/*drug effects Cells, Cultured Humans Keratinocytes/*physiology Ligands Naltrexone/pharmacology Narcotic Antagonists/*pharmacology Narcotics Receptors, Opioid, mu/*agonists Regeneration Skin/*cytology Wound Healing beta-Endorphin/*pharmacology
Pubmed
Web of science
Création de la notice
25/01/2008 17:30
Dernière modification de la notice
03/03/2018 13:22
Données d'usage